Commodore Capital LP Buys 1,042,681 Shares of PepGen, Inc. $PEPG

Commodore Capital LP grew its stake in shares of PepGen, Inc. (NASDAQ:PEPG) by 44.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,400,000 shares of the company’s stock after buying an additional 1,042,681 shares during the period. PepGen comprises 1.5% of Commodore Capital LP’s holdings, making the stock its 25th biggest position. Commodore Capital LP’s holdings in PepGen were worth $22,134,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Monashee Investment Management LLC purchased a new stake in shares of PepGen during the third quarter worth about $1,386,000. Boxer Capital Management LLC purchased a new position in PepGen during the 3rd quarter valued at approximately $1,155,000. Pictet Asset Management Holding SA increased its stake in PepGen by 181.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,352,424 shares of the company’s stock worth $8,804,000 after acquiring an additional 871,059 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of PepGen by 94.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock worth $73,000 after acquiring an additional 5,453 shares in the last quarter. Finally, Heights Capital Management Inc. bought a new position in shares of PepGen during the 3rd quarter valued at approximately $46,000. Institutional investors own 58.01% of the company’s stock.

Analyst Ratings Changes

PEPG has been the subject of several research reports. Wedbush lowered their price objective on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. HC Wainwright reissued a “buy” rating on shares of PepGen in a research note on Thursday, May 21st. Oppenheimer assumed coverage on PepGen in a report on Wednesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Weiss Ratings downgraded PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.50.

PepGen Trading Up 6.9%

Shares of PEPG stock opened at $1.70 on Thursday. PepGen, Inc. has a twelve month low of $1.01 and a twelve month high of $7.80. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $4.11. The stock has a market capitalization of $117.59 million, a price-to-earnings ratio of -0.97 and a beta of 1.93.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. Research analysts predict that PepGen, Inc. will post -1.2 EPS for the current fiscal year.

PepGen Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).